title: Alpha-galactose based neoglycopeptides. Inhibition of verotoxin binding to globotriosylceramide.
abstract: Solution and solid phase strategies for the synthesis of alpha-galactose based neoglycopeptide derivatives 2-13 were developed. Neoglycopeptides generated were tested for the inhibition of verotoxin binding to globotriosylceramide (Gb3) using ELISA. Among all of the compounds tested, only the lipid derivatives of neoglycopeptides, 11, 12 and 13 were found to be inhibitors, IC50 = 2.0 mM (11b and 12c) and 0.2 mM (11c and 13c). All of the inhibitors (11b, 11c, 12c and 13c) have a similar branching of the two alpha-galactosyl units at the N-terminal glycine residue of a short peptide and a lipid moiety attached at the C-terminal site. Both of these factors seem to be crucial for the inhibition. It is interesting to note that the inhibitors have only a portion of the natural trisaccharide ligand. The secondary groups either may contribute in sub-site oriented interactions with the protein receptors or may mimic the internal sugar units of the cell-surface ligand, Gb3.
authors.affiliation: Chemical Biology Program, Steacie Institute for Molecular Sciences, National Research Council of Canada, Ottawa, ON. prabhat.arya@nrc.ca
authors.forename: P
authors.initials: P
authors.lastname: Arya
authors.forename: K M
authors.initials: KM
authors.lastname: Kutterer
authors.forename: H
authors.initials: H
authors.lastname: Qin
authors.forename: J
authors.initials: J
authors.lastname: Roby
authors.forename: M L
authors.initials: ML
authors.lastname: Barnes
authors.forename: S
authors.initials: S
authors.lastname: Lin
authors.forename: C A
authors.initials: CA
authors.lastname: Lingwood
authors.forename: M G
authors.initials: MG
authors.lastname: Peter
mesh_terms: D000890:Anti-Infective Agents / Q000138:chemical synthesis / Q000737:chemistry / Q000494:pharmacology; D001427:Bacterial Toxins / Q000037:antagonists & inhibitors* / Q000378:metabolism*; D002240:Carbohydrate Sequence; D015195:Drug Design; D005690:Galactose / Q000737:chemistry*; D006020:Glycopeptides / Q000138:chemical synthesis / Q000737:chemistry* / Q000494:pharmacology*; D006801:Humans; D066298:In Vitro Techniques; D008024:Ligands; D009682:Magnetic Resonance Spectroscopy; D008954:Models, Biological; D008969:Molecular Sequence Data; D022622:Shiga Toxin 1; D013329:Structure-Activity Relationship; D014281:Trihexosylceramides / Q000378:metabolism*
chemical_list: D000890:Anti-Infective Agents; D001427:Bacterial Toxins; D006020:Glycopeptides; D008024:Ligands; D022622:Shiga Toxin 1; D014281:Trihexosylceramides; C018549:globotriaosylceramide; D005690:Galactose